PDF(Pubmed)
Abstract：
Cancer is a leading cause of death globally with childhood cancers accounting for around 5% of the total incidence. Almost 90% of childhood cancers are recorded from low-income and lower-middle-income countries (LLMICs), where survival rates are comparatively low. The unavailability of essential medicines for childhood cancers is identified as a reason for this observed health inequity. The objectives of this review are to describe the availability of cytotoxic medicines in the WHO essential medicine list (EML) used in treating children with cancer in LLMICs and to determine the enablers and barriers to accessing WHO essential medicines for childhood cancer.
A systematic review will be conducted using electronic databases: MEDLINE, EMBASE and CINAHL. Additional articles and grey literature will be searched in Google Scholar and reference list of the selected articles. It will include primary studies, national/regional reports and policy documents. Review questions will be framed into different components according to the ECLIPSe framework. Children less than 19 years of age diagnosed with any malignant disorder in LLMICs will be the client group. Studies that have focused on the availability of EML for adult malignancies and care providers\' knowledge of EML for childhood malignancies will not be considered. Only the studies reported in the English language will be included. Mixed methods Appraisal Tool will be used to assess the quality of included studies. Data will be presented as a narrative synthesis.
This research is exempt from ethics approval because the work is carried out on published documents. Findings of this review will be disseminated through a peer-reviewed journal for the authorities in LLMICs to understand the magnitude of the problem and to identify enablers and barriers to take evidence based decisions to improve their health system.
CRD42022334156.
A systematic review will be conducted using electronic databases: MEDLINE, EMBASE and CINAHL. Additional articles and grey literature will be searched in Google Scholar and reference list of the selected articles. It will include primary studies, national/regional reports and policy documents. Review questions will be framed into different components according to the ECLIPSe framework. Children less than 19 years of age diagnosed with any malignant disorder in LLMICs will be the client group. Studies that have focused on the availability of EML for adult malignancies and care providers\' knowledge of EML for childhood malignancies will not be considered. Only the studies reported in the English language will be included. Mixed methods Appraisal Tool will be used to assess the quality of included studies. Data will be presented as a narrative synthesis.
This research is exempt from ethics approval because the work is carried out on published documents. Findings of this review will be disseminated through a peer-reviewed journal for the authorities in LLMICs to understand the magnitude of the problem and to identify enablers and barriers to take evidence based decisions to improve their health system.
CRD42022334156.
摘要：
背景：癌症是全球死亡的主要原因，儿童癌症约占总发病率的5％。近90%的儿童癌症来自低收入和中低收入国家(LLMICs)。存活率相对较低。儿童癌症缺乏基本药物被认为是这种观察到的健康不平等的原因。本综述的目的是描述世卫组织基本药物清单(EML)中用于治疗LLMICs儿童癌症的细胞毒性药物的可用性，并确定获得世卫组织儿童癌症基本药物的推动因素和障碍。
方法：将使用电子数据库进行系统审查：MEDLINE，EMBASE和CINAHL。其他文章和灰色文献将在Google学者和所选文章的参考列表中搜索。它将包括初级研究，国家/区域报告和政策文件。审核问题将根据ECLIPSe框架分为不同的组成部分。在LLMICs中被诊断患有任何恶性疾病的19岁以下的儿童将是客户群体。关注成人恶性肿瘤的EML可用性和护理提供者对儿童恶性肿瘤的EML知识的研究将不被考虑。仅包括以英语报告的研究。混合方法评估工具将用于评估纳入研究的质量。数据将作为叙述性综合呈现。
背景：这项研究免于伦理批准，因为该工作是在已发布的文件上进行的。这项审查的结果将通过同行评审的期刊传播，供低收入国家的当局了解问题的严重性，并确定采取循证决策以改善其卫生系统的推动者和障碍。
■CRD42022334156。
方法：将使用电子数据库进行系统审查：MEDLINE，EMBASE和CINAHL。其他文章和灰色文献将在Google学者和所选文章的参考列表中搜索。它将包括初级研究，国家/区域报告和政策文件。审核问题将根据ECLIPSe框架分为不同的组成部分。在LLMICs中被诊断患有任何恶性疾病的19岁以下的儿童将是客户群体。关注成人恶性肿瘤的EML可用性和护理提供者对儿童恶性肿瘤的EML知识的研究将不被考虑。仅包括以英语报告的研究。混合方法评估工具将用于评估纳入研究的质量。数据将作为叙述性综合呈现。
背景：这项研究免于伦理批准，因为该工作是在已发布的文件上进行的。这项审查的结果将通过同行评审的期刊传播，供低收入国家的当局了解问题的严重性，并确定采取循证决策以改善其卫生系统的推动者和障碍。
■CRD42022334156。
